This in vitro diagnostic substances, reagents, test kits and sets federal contracting opportunity for Center for Biologics Evaluation and Research, Health and Human Services, provides in-vitro diagnostic substance manufacturing products and/or services. The original notice was posted on June 01, 2020 and last updated June 17, 2020 with a response date of June 23, 2020.
Most recently (June 17, 2020), the source selection notice, response date was moved to Jun 23, 2020 and description was updated.
The buyer (FDA - Center for Biologics Evaluation and Research) from Health and Human Services spent $0k in federal contracting dollars in fiscal year 2023 with a stable budget forecast heading into FY24. FDA - Center for Biologics Evaluation and Research shows no competition preference for set asides with in set aside dollars (versus full and open competiton).
Imagine a world where every report, every insight is tailored specifically to you. Our entire platform is configured around your past performance so that everything is relevant.
We start with the largest federal opportunity database, including forecasts and re-competes, and add layer a suite of pipeline management tools.
Our market-centric platform adds context to every pursuit. Every opportunity, every report, tailored specifically to you.
Find gaps in the market, identify key competitors and teaming partners, evaluate performance, and analyze pathways to new business.
Federal Compass is software designed for today’s federal market.
Explore how the right intel and process can help lead your team to greater success.
Enjoy instant access to the Federal Compass platform